17-Hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model

Hypertension

Volumn 65, Issue 1, 2015, Pages 225-231

  Amaral, Lorena M ^a   Cornelius, Denise C ^a   Harmon, Ashlyn ^a   Moseley, Janae ^a   Martin, James N ^a   LaMarca, Babbette ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Hypertension; Inflammation; Nitric Oxide; Pregnancy; Progesterone

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYPROGESTERONE CAPROATE; NITRATE; NITRITE; TUMOR NECROSIS FACTOR ALPHA; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; ANTIESTROGEN; PROGESTERONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; BIOAVAILABILITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; GESTATIONAL AGE; INFLAMMATION; INTRAUTERINE PRESSURE; MEAN ARTERIAL PRESSURE; NONHUMAN; PREECLAMPSIA; PROTEIN EXPRESSION; RAT; VASODILATATION; ANIMAL; BLOOD PRESSURE; BREEDING; DISEASE MODEL; DRUG EFFECTS; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; UTERINE ARTERY; VASCULAR RESISTANCE;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ESTROGEN ANTAGONISTS; FEMALE; HYDROXYPROGESTERONES; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY, ANIMAL; PROGESTERONE CONGENERS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; UTERINE ARTERY; VASCULAR RESISTANCE; VASODILATION;

EID: 84919424380     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04484     Document Type: Article

References (40)

1. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol. 1997;37:240-249.
2. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294:H541-H550.
3. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol. 2010;62:105-120.
4. Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res. 2010;36:239-247.
5. Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nat Clin Pract Nephrol. 2005;1:98-114, quiz 120.
6. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594.
7. Sandrim VC, Montenegro MF, Palei AC, Metzger IF, Sertorio JT, Cavalli RC, Tanus-Santos JE. Increased circulating cell-free hemoglobin levels reduce nitric oxide bioavailability in preeclampsia. Free Radic Biol Med. 2010;49:493-500.
8. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799.
9. Roberts JM, Pearson G, Cutler J, Lindheimer M; NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI Working Group on research on hypertension during pregnancy. Hypertension. 2003;41:437-445.
10. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006;8:1-20.
11. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brsen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Müller DN. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension. 2005;45:742-746.
12. Granger JP. Inflammatory cytokines, vascular function, and hypertension. Am J Physiol Regul Integr Comp Physiol. 2004;286:R989-R990.
13. Herse F, LaMarca B. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol. 2013;69:413-418.
14. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
15. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J. 2010;10:40-45.
16. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945-952.
17. Brewer J, Liu R, Lu Y, Scott J, Wallace K, Wallukat G, Moseley J, Herse F, Dechend R, Martin JN Jr, Lamarca B. Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension. 2013;62:886-892.
18. Meis PJ. The role of 17 alpha-hydroxyprogesterone caproate in the prevention of preterm birth. Womens Health (Lond Engl). 2006;2:819-824.
19. Merlob P, Stahl B, Klinger G. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. Reprod Toxicol. 2012;33:15-19.
20. Sfakianaki AK, Norwitz ER. Mechanisms of progesterone action in inhibiting prematurity. J Matern Fetal Neonatal Med. 2006;19:763-772.
21. Kiprono LV, Wallace K, Moseley J, Martin J Jr, Lamarca B. Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemia. Am J Obstet Gynecol. 2013;209:44.e1-44.e6.
22. Keiser SD, Veillon EW, Parrish MR, Bennett W, Cockrell K, Fournier L, Granger JP, Martin JN Jr, Lamarca B. Effects of 17-hydroxyprogesterone on tumor necrosis factor-alpha-induced hypertension during pregnancy. Am J Hypertens. 2009;22:1120-1125.
23. Veillon EW Jr, Keiser SD, Parrish MR, Bennett W, Cockrell K, Ray LF, Granger JP, Martin JN Jr, LaMarca B. 17-Hydroxyprogesterone blunts the hypertensive response associated with reductions in uterine perfusion pressure in pregnant rats. Am J Obstet Gynecol. 2009;201:324.e1-324.e6.
24. Selles J, Polini N, Alvarez C, Massheimer V. Progesterone and 17 betaestradiol acutely stimulate nitric oxide synthase activity in rat aorta and inhibit platelet aggregation. Life Sci. 2001;69:815-827.
25. Simoncini T, Fu XD, Caruso A, Garibaldi S, Baldacci C, Giretti MS, Mannella P, Flamini MI, Sanchez AM, Genazzani AR. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod. 2007;22:2325-2334.
26. Amaral LM, Kiprono L, Cornelius DC, Shoemaker C, Wallace K, Moseley J, Wallukat G, Martin JN Jr, Dechend R, LaMarca B. Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy. Am J Obstet Gynecol. 2014;211:158.e1-158.e6.
27. Tam Tam KB George E, Cockrell K, Arany M, Speed J, Martin JN Jr, Lamarca B, Granger JP. Endothelin type a receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol. 2011;204(4):330.e1-4.
28. Lamarca B, Speed J, Ray LF, Cockrell K, Wallukat G, Dechend R, Granger J. Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation. Int J Infereron Cytokine Mediator Res. 2011;2011:65-70.
29. Prins JR, Boelens HM, Heimweg J, Van der Heide S, Dubois AE, Van Oosterhout AJ, Erwich JJ. Preeclampsia is associated with lower percentages of regulatory T cells in maternal blood. Hypertens Pregnancy. 2009;28:300-311.
30. Toldi G, Svec P, Vásárhelyi B, Mszáros G, Rigó J, Tulassay T, Treszl A. Decreased number of FoxP3+ regulatory T cells in preeclampsia. Acta Obstet Gynecol Scand. 2008;87:1229-1233.
31. Toldi G, Saito S, Shima T, Halmos A, Veresh Z, Vásárhelyi B, Rigó J Jr, Molvarec A. The frequency of peripheral blood CD4+ CD25high FoxP3+ and CD4+ CD25- FoxP3+ regulatory T cells in normal pregnancy and pre-eclampsia. Am J Reprod Immunol. 2012;68:175-180.
32. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9:480-485.
33. Wallace K, Richards S, Dhillon P, Weimer A, Edholm ES, Bengten E, Wilson M, Martin JN Jr, LaMarca B. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension. 2011;57:949-955.
34. Novotny SR, Wallace K, Heath J, Moseley J, Dhillon P, Weimer A, Wallukat G, Herse F, Wenzel K, Martin JN Jr, Dechend R, Lamarca B. Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats. Am J Physiol Regul Integr Comp Physiol. 2012;302:R1197-R1201.
35. Novotny S Wallace K, Herse F, Moseley J, Darby M, Heath J, Gill J, Wallukat G, Martin JN, Dechend R, Lamarca B. Cd4+ t cells play a critical role in mediating hypertension in response to placental ischemia. J Hypertens. 2013;2:116.
36. LaMarca B, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, Granger JP. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension. 2008;52:1161-1167.
37. Thomas P, Pang Y. Protective actions of progesterone in the cardiovascular system: potential role of membrane progesterone receptors (mPRs) in mediating rapid effects. Steroids. 2013;78:583-588.
38. Nelson SH, Steinsland OS, Wang Y, Yallampalli C, Dong YL, Sanchez JM. Increased nitric oxide synthase activity and expression in the human uterine artery during pregnancy. Circ Res. 2000;87:406-411.
39. Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am J Physiol Heart Circ Physiol. 2001;280:H1699-H1705.
40. Meher S, Duley L. Progesterone for preventing pre-eclampsia and its complications. The Cochrane Database of Systematic Reviews. 2006:CD006175.